Chi Kong Li
Quick facts
Phase 2 pipeline
- CUCART19 · Infectious Disease
CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies